Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma Journal Article
| Authors: | Duffy, A.; Shia, J.; Huitzil-Melendez, F. D.; Fong, Y.; O'Reilly, E. M. |
| Article Title: | Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma |
| Abstract: | A 32-year-old Asian male presented with perforated sigmoid colorectal cancer (CRC) and large, unresectable hepatic metastasis. After surgery for his primary tumor, he received 6 months of FOLFOX (5-fluorouracil/leucovorin/ oxaliplatin) plus bevacizumab and achieved a partial response. He underwent hepatic metastasectomy and was found to have had a complete pathologic response (pCR) to treatment. The literature regarding pCR with chemotherapy in CRC and the implications for further management is discussed herein. |
| Keywords: | adult; treatment outcome; treatment response; clinical feature; case report; bevacizumab; fluorouracil; monotherapy; liver neoplasms; cancer adjuvant therapy; neoadjuvant therapy; follow up; laparotomy; computer assisted tomography; antineoplastic combined chemotherapy protocols; camptothecin; combination chemotherapy; irinotecan; colorectal carcinoma; colorectal neoplasms; antibodies, monoclonal; folinic acid; colon resection; oxaliplatin; angiogenesis inhibitors; organoplatinum compounds; leucovorin; hepatic metastasis; retroperitoneal lymphadenopathy |
| Journal Title: | Clinical Colorectal Cancer |
| Volume: | 7 |
| Issue: | 2 |
| ISSN: | 1533-0028 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2008-03-01 |
| Start Page: | 140 |
| End Page: | 143 |
| Language: | English |
| DOI: | 10.3816/CCC.2008.n.019 |
| PUBMED: | 18501074 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 2" - "Export Date: 17 November 2011" - "CODEN: CCCLC" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work